All In Biotech

NDA 020171 · Fresenius Medcl

Delflex W/ Dextrose 4.25% Low Magnesium Low Calcium In Plastic Container

Calcium Chloride, Dextrose, Magnesium Chloride, Sodium Chloride, Sodium Lactate · Intraperitoneal

Last checked: Nov 19, 2026Latest source record: Jan 26, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Aug 19, 1992

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9,299

2,122 Phase 3, 968 recruiting

FAERS reports

8,955

4,867 serious, 685 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 30, 2026.

1. INDICATIONS AND USAGE DELFLEX® is indicated in the treatment of chronic kidney failure patients being maintained on peritoneal dialysis For treatment of chronic kidney failure. ( 1 )

Mechanism: DELFLEX peritoneal dialysis solutions are hypertonic peritoneal dialysis solutions containing dextrose, a monosaccharide, as the primary osmotic agent. An osmotic gradient must be created between the peritoneal membrane and the dialysis solution in order for ultrafiltration to occur. The hypertonic concentration of glucose in DELFLEX solutions exert an osmotic pressure across the peritoneal membrane resulting in transcapillary ultrafiltration. Like other peritoneal dialysis solutions, DELFLEX solutions contain electrolytes to facilitate the correction of acid-base and electrolyte...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 19, 1992 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER · CALCIUM CHLORIDE 18.4MG/100ML; DEXTROSE 4.25GM/100ML; MAGNESIUM CHLORIDE 5.08MG/100ML; SODIUM CHLORIDE 538MG/100ML; SODIUM LACTATE 448MG/100ML · SOLUTION, INTRAPERITONEAL · Prescription · TE AT
  • DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER · CALCIUM CHLORIDE 18.4MG/100ML; DEXTROSE 1.5GM/100ML; MAGNESIUM CHLORIDE 5.08MG/100ML; SODIUM CHLORIDE 538MG/100ML; SODIUM LACTATE 448MG/100ML · SOLUTION, INTRAPERITONEAL · Prescription · TE AT
  • DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER · CALCIUM CHLORIDE 18.4MG/100ML; DEXTROSE 2.5GM/100ML; MAGNESIUM CHLORIDE 5.08MG/100ML; SODIUM CHLORIDE 538MG/100ML; SODIUM LACTATE 448MG/100ML · SOLUTION, INTRAPERITONEAL · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.

All 9,299 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • peritonitis1,624
  • peritonitis bacterial972
  • abdominal distension614
  • abdominal pain432
  • death343
  • malaise325
  • bloody peritoneal effluent288
  • dyspnoea286
  • pain278
  • infection274
  • fluid overload267
  • discomfort223

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20121
201318
2014127
2015456
2016721
2017764
20181,362
2019986
2020523
2021834
2022902
2023507
2024577
2025705
2026471

Recalls

13 FDA enforcement reports for this application.

  • Oct 14, 2026 · Class II · Ongoing

    Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.

  • Oct 14, 2026 · Class II · Ongoing

    Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.

  • Oct 14, 2026 · Class II · Ongoing

    Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.

  • Oct 14, 2026 · Class II · Ongoing

    Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.

  • Oct 14, 2026 · Class II · Ongoing

    Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.

  • Jun 18, 2024 · Class II · Ongoing

    This product is being recalled due to the tube weld failure presents itself as a slow leak and can be difficult to detect.

  • Dec 28, 2023 · Class II · Ongoing

    Lack of Sterility Assurance

  • Apr 28, 2021 · Class III · Terminated

    Temperature Abuse: Product exposed to temperature outside specified limits.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Mar 10, 2026

    DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2L, 5/cs (NDC 49230-209-92). The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.

  • To Be Discontinued · updated Mar 10, 2026

    DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-209-94). The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.

  • To Be Discontinued · updated Mar 10, 2026

    DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2L, 5/cs (NDC 46163-206-92). The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.

  • To Be Discontinued · updated Sep 10, 2026

    DELFLEX, Solution, 18.4 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 46163-212-95). A business decision was made to discontinue manufacture of the drug.

  • To Be Discontinued · updated Mar 10, 2026

    DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 46163-212-94). The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.

  • To Be Discontinued · updated Mar 10, 2026

    DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2L, 5/cs (NDC 46163-212-92). The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,091 on PubMed

Sponsor: Fresenius Medcl · Also marketed as Delflex W/ Dextrose 1.5% Low Magnesium Low Calcium In Plastic Container, Delflex W/ Dextrose 2.5% Low Magnesium Low Calcium In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.